Is Romosozumab (Evenity) contraindicated in patients who have previously undergone radiation therapy?

Evenity (Romosozumab) is NOT Contraindicated in Patients with Prior Radiation Exposure

Romosozumab can be safely used in patients who have previously undergone radiation therapy. This is explicitly stated in the 2020 AACE/ACE guidelines, which note that "Romosozumab can be used in patients with prior radiation exposure" 1.

Key Points About Romosozumab Use

Actual Contraindications (Per FDA Label)

The FDA-approved contraindications for Evenity are limited to 2:

• Hypocalcemia (must be corrected before starting)
• History of systemic hypersensitivity to romosozumab (angioedema, erythema multiforme, urticaria)

Black Box Warning - Cardiovascular Risk

The only major safety concern is cardiovascular, NOT radiation history 2:

• Should not be initiated in patients who had myocardial infarction or stroke within the preceding year
• Use caution in patients with other cardiovascular risk factors
• This warning stems from the ARCH trial where romosozumab showed higher cardiovascular events compared to alendronate (hazard ratio 1.87) 2

Clinical Context for Radiation History

Patients who have received radiation therapy often develop:

• Radiation-induced bone loss and atrophy
• Insufficiency fractures in irradiated fields (common in pelvis, ribs)
• Increased fracture risk from direct bone damage and vascular changes 3

These patients may actually benefit from romosozumab's potent bone-building effects, as it provides:

• Dramatic increases in bone mineral density (17.7% spine, 4.1% hip at 12 months) 1
• 73% reduction in vertebral fractures vs placebo 1
• Both anabolic (bone formation) and antiresorptive effects 1

Clinical Decision Algorithm

For patients with prior radiation exposure considering osteoporosis treatment:

1. Assess cardiovascular risk first - this is the determining factor, not radiation history

   • Recent MI/stroke within 1 year? → Contraindicated
   • High cardiovascular risk factors? → Consider benefits vs risks carefully
   • Low cardiovascular risk? → Romosozumab is appropriate

2. Evaluate fracture risk severity

   • Very high risk (recent major fracture, multiple vertebral fractures)? → Romosozumab is preferred first-line 4
   • High risk? → Romosozumab or denosumab over bisphosphonates 5

3. Check for hypocalcemia - correct before starting 2

4. Plan sequential therapy - romosozumab is limited to 12 monthly doses, must be followed by antiresorptive (denosumab or bisphosphonate) 1, 4

Common Pitfall to Avoid

Do not confuse radiation exposure with the cardiovascular contraindication. The guidelines explicitly separate these issues - radiation history is mentioned as a permissible scenario, while cardiovascular disease is the actual concern 1.